IL6 and major depressive disorder: We propose a proof-of-concept, randomised, parallel-group, double-blind, placebo controlled clinical trial to investigate whether IL-6 contributes to pathogenesis of depression and to examine potential mechanisms by which IL-6 affects mood and cognition.